There are 2934 resources available
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
When common cancers become rare- the lung cancer experience
Presenter: Simon Ekman
Session: Common but still rare: What happens when common cancers split into subgroups?
Resources:
Slides
Webcast
The Ros1ders: An advocacy experience
Presenter: Merel Hennink
Session: Common but still rare: What happens when common cancers split into subgroups?
Resources:
Slides
Webcast
How to deal with diversity early on: Personalised early clinical trials
Presenter: Matthias Scheffler
Session: Common but still rare: What happens when common cancers split into subgroups?
Resources:
Slides
Webcast
What common cancer advocates can learn from the rare cancer community
Presenter: Iain Galloway
Session: Common but still rare: What happens when common cancers split into subgroups?
Resources:
Slides
Webcast
4154 - TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment
Presenter: Matteo Canale
Session: Poster Display session 1
Resources:
Abstract
1175 - HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
Presenter: Kimio Yonesaka
Session: Poster Display session 1
Resources:
Abstract